GRI Stock Catalyst: GRI Bio Reports Interim 6-Week Lung Function Results for GRI-0621 in Phase 2a IPF Study

Sep 10, 2025 · 7:58pm ET

Results show a 2:1 ratio of improvement over placebo.

Max move

+127.7%

High of day $101.36

Sparker timei

7:58pm ET

GRI · Sep 10, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

GRI Bio, Inc. announced on 2025-09-11 GRI Bio reported interim 6-week lung function results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), with results compared to placebo.

The announcement cited 6 weeks, 2:1 ratio, and 12 weeks.

GRI Bio, Inc. Common Stock has a free float of 2,514,800 shares and 2,515,300 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time GRI sparks.

Download Sniper App →

Catch the next GRI-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →